Skip to main content
Anjali Advani, MD, Oncology, Cleveland, OH

Anjali S Advani MD

Hematologic Oncology


Director, Inpatient Leukemia Unit, Cleveland Clinic Taussig Cancer Institute Professor of Medicine, Cleveland Clinic Lerner College of Medicine

Join to View Full Profile
  • 10201 Carnegie AvenueDesk CA60Cleveland, OH 44195

  • Phone+1 216-445-9354

  • Fax+1 216-444-9464

Dr. Advani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology and Medical Oncology, 1999 - 2002
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1996 - 1999
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1996

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2002 - 2025
  • NC State Medical License
    NC State Medical License 1997 - 2003
  • Hematology
    American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML  
    Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

  • Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
    Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
    Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
    Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Ponatinib Linked with Better Outcomes Than Imatinib in Philadelphia Chromosome-Positive ALL
    Ponatinib Linked with Better Outcomes Than Imatinib in Philadelphia Chromosome-Positive ALLMarch 17th, 2023
  • New Treatment Combination Without Chemotherapy Is Effective in PH+ Acute Lymphoblastic Leukemia
    New Treatment Combination Without Chemotherapy Is Effective in PH+ Acute Lymphoblastic LeukemiaDecember 13th, 2021
  • Addition of Ixazomib to MEC Chemotherapy Promising in R/R AML
    Addition of Ixazomib to MEC Chemotherapy Promising in R/R AMLAugust 30th, 2019
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: